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Two independent studies in this issue of Cell Stem Cell (Liao et al., 2009; Li et al., 2009) derive rat induced
pluripotent stem cells (iPSCs). In one report, the method used results in rat and human iPSCs that exhibit
phenotypic traits similar to mouse embryonic stem cells.Robust pluripotent embryonic stem cells
(ESCs) have been derived from mouse,
human, and several monkey species.
However, attempts to develop pluripotent
cell lines from other rodents, domestic
animal species, and endangered animals
has been largely unsuccessful to date
(Keefer et al., 2007; Ueda et al., 2008).
Two independent reports in this issue
(Liao et al., 2009; Li et al., 2009) report
the production of induced pluripotent
stem cells (iPSCs) in the rat. These
findings represent a significant and inter-
esting development that carries important
potential implications formedical science,
cell biology, and animal conservation.
The studies reported by Liao et al.
(2009) show that rat primary skin fibro-
blasts and bone marrow cells may be
reprogrammed using lentiviral vectors
that expressed the conventional reprog-
ramming Oct4, Sox2,c-Myc, and Klf4
transcription factor genes. Interestingly,
the authors were unable to achieve re-
programming using retroviral vectors or
lentiviral constructs that expressed
Nanog and Lin28 instead of c-Myc and
Klf4. The rat iPSCs (riPSCs) could be
stably maintained on mouse embryonic
fibroblasts (MEF) with human ESC
medium for at least 36 to 38 passages
in vitro, were capable of differentiation
into all three germ lineages (ectoderm,
mesoderm, and endoderm) in vitro, and
formed teratomas when injected into
immune-compromised mice. In this re-
gard the riPSCs behave much like human
ESCs and iPSCs. An additional similarity
between induced pluripotent cells from
the two species is that neither have been
shown to contribute to embryonic chime-
rism, although this failure may be due to
the lack of suitable assays. It is interesting
that reprogramming of rat cells by theconventional transcription factor cocktail
gives rise to colonies that share at least
some traits with human cells rather than
with mouse iPSCs.
The apparent differences between
mouse and human ESCs and iPSCs and
how these growth factor distinctions
might relate to the formation of riPSCs
and human iPSCs (hiPSCs) was the
principal focus of the studies reported
by Li et al. (2009). In this case, the authors
made use of the divergent pathways that
control mouse and human pluripotent
cell renewal and differentiation to design
conditions for creating iPSCs. The con-
ditions that succeeded, as well as
those that did not, reveal particularly inter-
esting outcomes. Their hypotheses were
based on the observation that murine
ESCs derived from preimplantation blas-
tocysts give rise to distinct cell colonies
that are different from the ESCs gener-
ated from the epiblast of implanted
embryos. The latter resemble human
ESCs in morphology, and in the response
to growth factors and pathways for
renewal and differentiation (Brons et al.,
2007; Tesar et al., 2007). Specifically,
mouse ESCs require BMP4 to inhibit
ERK activation, whereas ERK is active in
human ESCs and those made from
mouse epiblasts. Therefore, the authors
used a MEK inhibitor in combination with
GSK3 inhibition to elevate the Wnt
signaling cascade. They further stabilized
the cultures with an inhibitor of the type
1 TGFb receptor and reprogrammed
rat liver cells to riPSCs using retroviral
vectors that contained Oct4, Sox2, and
Klf4. These riPSCs could be stably main-
tained as clonal lines with a phenotype
resembling mouse ESCs. Like mouse
ESCs, long-term maintenance of the
riPSCs required the presence of LIF inCell Stem Crenewal cultures. Consequently, these
reprogrammed rat cells are very similar
to mouse ESCs and, like these cells, can
differentiate into all three germ lineages
in vitro, produce teratomas in vivo, and
result in chimerism when injected into
wild-type rat blastocysts. It remains to
be seen whether the difference in the
phenotypes of the riPSCs derived by the
two groups stems from the difference in
starting cell population, reprogramming
factors used, or the selection conditions
applied during derivation of the lines.
Furthermore, Li and colleagues used
a retroviral derivation method involving
Oct4, Sox2, Nanog, and Lin28 genes and
the growth factor/inhibitor cocktail that
succeeded in maintaining riPSCs to
produce hiPSCs that also resemblemouse
ESCs in morphology and growth factor
responses during renewal and differentia-
tion. These cells were maintained for
more than 20 passages and exhibited
similar differentiation potential as has
been observed for ESCs in vitro and
in vivo. The authors propose that the
hiPSCs derived in the presence of the
inhibitor cocktail areat least phenotypically
equivalent tomouseESCsandalsodistinct
from conventionally derived human ESCs.
The opportunity to equate populations of
human and mouse pluripotent cells may
assist in using mouse ESC data to inform
studies of human pluripotent stem cell
functionboth inculture andafter transplan-
tation. However, while potentially signifi-
cant, the conclusion that the hiPSCs
described by Ding and colleagues are
equivalent to mESCs remains to be tested
in additional comparative experiments.
No matter how similar mouse, rat, and
human iPSCs might be, it remains to
be seen whether the usefulness of human
iPSCs can be established, given theell 4, January 9, 2009 ª2009 Elsevier Inc. 3
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Previewspresence of viral sequences and of
multiple copies of the transcription factors
in potentially unregulated sites in the
human genome. Regulatory agencies are
likely to consider these lines to be geneti-
cally engineered and will consequently
hold them to a very high bar in order to
establish safety for use in human therapy.
On the other hand, the potential availability
of riPSCs for modeling human diseases
will be very attractive to researchers and
companies involved in drug discovery, as
the mouse has often proven inadequate
as a model for candidate therapeutics. In
order to serve as a useful research tool,
gene targeting of the riPSCs must be
accomplished with relative ease, and the
production of chimeric offspring will need
to become routine. With respect to the
latter, Li et al. (2009) have shown that
chimerism is possible with a small number
of blastocyst injections.
The field of stem cell research will
certainly embrace these new develop-
ments in iPSC research. In addition, one
can predict that similar approaches will
be undertaken to determine whether
other species will prove amenable to re-
programming, such as such as horses
and household pets. Indeed, iPSCs have
recently been generated from nonhuman
primates (Liu et al., 2008). The usefulness
of iPSCs in pigs, cattle, sheep, etc., may
also be demonstrated in time. However,4 Cell Stem Cell 4, January 9, 2009 ª2009 Ethe practice of cloning sheep, cattle, and
pigs has not been sustained due to the
developmental abnormalities that have
been observed in cloned offspring. Thus,
the potential of iPSC-derived chimeric
males for use in breeding is of arguable
benefit and unlikely to be widely adopted.
Nonetheless, there will be interest from
animal conservationists to explore the
opportunity for recovery of endangered
species by forming chimeras with closely
related species, if available (Tecirlioglu
et al., 2006; Beyhan et al., 2007), and
perhaps even to rescue extinct species if
appropriate cells or tissues have been
cryobanked.
Clearly, the presence of viral elements
and potentially unregulated genes is
a danger for the sustained health of any
chimeric species, and any endogenous
genes that are not properly reprog-
rammed in the iPSCs are potentially
hazardous, as has been observed in
animal cloning. Much work is needed to
remove the dangers that remain within
genetically altered iPSCs if they are ever
to be used for transplantation or human
cell therapeutics. To this end, the rapid
pace of the iPSC field continues, and
progress toward the goal of eliminating
oncogenes and viral genomic insertions
has been reported recently (reviewed in
Maherali and Hochedlinger, 2008). Over-
all, the availability of rat iPSCs offerslsevier Inc.a new and potentially powerful model for
discoveries in human medicine.
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